Manish Jha
University of Texas Southwestern Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Manish Jha as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07825857 · Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderUniversity of Texas Southwestern Medical Center · recruiting · Methamphetamine Use Disorder · principal investigator
- Ph2NCT07693608 · An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use DisorderUniversity of Texas Southwestern Medical Center · active not recruiting · Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder · principal investigator
- Ph2NCT06745128 · Tirzepatide for Obesity and Meth Use DisorderUniversity of Texas Southwestern Medical Center · completed · Obesity, Methamphetamine Use Disorder · principal investigator
- N/ANCT06424184 · Accelerated rTMS for Substance Use Disorder and DepressionUniversity of Texas Southwestern Medical Center · recruiting · Stimulant Use, Depression · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderUG3DA066252 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2026 · $2,792,991 awarded in 2026Same name and institution; not confirmed by an ID
- Elucidating the Neurocircuitry of Irritability with Ultra-High-Field Neuroimaging to Identify Novel Therapeutic TargetsK23MH126202 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2021 to 2025 · $182,520 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:38 UTC. The ranking covers the 200 most relevant of 58 PubMed records, and a shared surname and initials can bring in a namesake. All 58 on PubMed
- Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.N Engl J Med · 2023230 citationsRCR 33.3
- A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.Am J Psychiatry · 2021173 citationsRCR 14.1
- Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.Psychoneuroendocrinology · 2017163 citationsRCR 7.1
- Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression.Am J Psychiatry · 2020100 citationsRCR 5.9
- Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study.Psychol Med · 201989 citationsRCR 4.6
- 73 citationsRCR 12.0
- Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder: Secondary Analysis of a Randomized Clinical Trial.JAMA Psychiatry · 202071 citationsRCR 4.4
- Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.Am J Psychiatry · 202165 citationsRCR 4.3
- Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.J Affect Disord · 201850 citationsRCR 2.4
- Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial.Mol Psychiatry · 202450 citationsRCR 10.5